CClinicalTrials.gg
Not yet recruitingNCT07788872MORESPUpdated Aug 27, 2026

More Realistic Spine Patients: Assessing the Effect of Dialogue Support Tool.

An interventional study of Dialogue Support Consultation in Spinal Stenosis Lumbar, Disc Herniation, Lumbar and Degenrative Disc Disease, sponsored by University Hospital, Akershus. Not yet recruiting at 2 sites in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-27.

Sponsored by University Hospital, Akershus · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
440
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This multicenter randomized controlled trial will evaluate whether an additional preoperative consultation using the Dialogue Support (DS) tool improves patient information, expectations, and outcomes among adults scheduled for lumbar spine surgery for degenerative spinal disorders.

The DS tool predicts outcomes one year after surgery based on patient characteristics and presents these estimates numerically and visually. Participants will be randomized to either standard preoperative care or standard care plus an additional consultation in which DS results are presented and explained.

The study will assess whether the additional DS consultation influences postoperative outcomes, preoperative expectations, surgery cancellations, and cost-effectiveness. In addition, the project will externally validate the DS tool using data from the Norwegian Registry for Spine Surgery (NORspine) and assess the inter-rater reliability of DS assessments across spine surgeons.

Read the detailed description

In Norway, data from the Norwegian Registry for Spine Surgery (NORspine) indicate that the proportion of patients reporting improvement 12 months after lumbar spinal surgery ("success rate") ranges from 63% to 67%. This suggests that a considerable proportion of patients remain dissatisfied, and that spinal surgery carries an inherent risk of symptom deterioration.

Studies have shown that patients frequently hold high preoperative expectations, yet only approximately 30% ultimately achieve their anticipated clinical outcome. Likewise, surgeons may overestimate the potential benefits of surgery while underestimating the likelihood of unfavourable outcomes.

The overall costs associated with spine surgery are substantial, and unsuccessful procedures have significant consequences for patients' health-related quality of life and impose a considerable economic burden on society. The advisory board of NORspine has therefore recommended that Norwegian hospitals promote studies to improve surgical outcomes.

Tools that improve surgeon-patient communication and facilitate patients' understanding of the medical information provided may be a useful strategy for reducing unfavourable outcomes. With the rapid advancement of digital technology and artificial intelligence, healthcare systems should consider implementing validated prognostic tools to support informed decision-making. However, these tools must undergo rigorous evaluation to ensure real-world applicability and to assess their impact on the healthcare system.

One such tool is the Dialogue Support (DS) application, an online platform based on the Swedish national quality register for spine patients (Swespine), designed to predict outcomes one year after surgery for degenerative spinal disorders. The DS application has been publicly available since October 2020 through a collaboration between the Eurospine steering board and the Swedish Society of Spinal Surgeons. The predicted outcomes are presented both numerically and graphically via a pie chart, thereby facilitating patients' comprehension of potential outcomes, including the possibility of symptom deterioration in the worst-case scenario. Additionally, second-opinion consultations may serve as a safeguard by providing patients scheduled for surgery or conservative treatment with repeated information.

This project will investigate the use of the DS application as a supplementary information and communication tool for patients with degenerative spinal disorders. The overarching aim is to improve patient treatment and specialised care through clinical research.

A multicenter superiority randomised controlled trial (RCT) will be conducted, in which the intervention consists of one additional consultation using the DS tool, referred to as the interventional consultation. The RCT design ensures equal study groups and allows for comparison of groups treated during the same period, by the same surgeons, and under identical clinical guidelines, thereby effectively eliminating confounders and reducing bias.

All patients aged 18 years or older who are scheduled to undergo lumbar spinal surgery for disc herniation, spinal stenosis, or degenerative disc disease will be eligible for inclusion. Patients who do not understand spoken or written Norwegian will be excluded, as language barriers may interfere with the intervention consultation, comprehension of the information provided, and completion of study questionnaires. Additional exclusion criteria include patients with spondylolysis or lytic spondylolisthesis, as well as those already participating in other clinical studies.

Eligible patients will receive verbal and written information about the study and will sign an informed consent form if willing to participate. Randomisation will assign eligible patients to one of two arms: either no additional consultation before planned surgery or one additional consultation using the DS tool. Blinding of patients and surgeons will not be feasible. To account for an anticipated dropout rate of 25%, a total of 440 patients will be included for analysis of the primary outcome. REDCap will be used for stratified block randomisation, with stratification based on diagnosis-disc herniation, spinal stenosis, or degenerative disc disease-to ensure balanced allocation across subgroups. Variable block sizes will be used to reduce the predictability of allocation sequences. Randomisation will be performed separately within each participating hospital to ensure balance between intervention and control groups and to minimise centre-related confounding.

The interventional DS consultation will follow the same framework as the standard preoperative consultation and will be scheduled approximately 2 to 6 weeks before surgery. Patients are required to complete a questionnaire to collect the baseline data required for the DS tool, as well as the Oswestry Disability Index (ODI) and EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaires, either in paper or electronic format, before the interventional consultation.

The consultation will occur in the outpatient clinic and is expected to last approximately 30 to 40 minutes, conducted in person to facilitate communication. The DS results will be presented and explained to the patient, who will have the opportunity to ask questions about the surgical procedure, potential complications, the hospital course, discharge, and recovery period. The primary aim of this consultation is to enhance patient understanding; it is not intended to revisit or discuss the surgical indication.

Follow-up will be conducted at 3 and 12 months, in line with the Norwegian spine registry, and will include the same Patient-Reported Outcome Measures (PROMs) as the registry (ODI, NRS back and leg pain, GPE translation scale). This approach will facilitate collaboration with the Norwegian Spine Registry and minimise the number of follow-up forms for patients. Radiological examinations will not be performed as part of this study.

Four studies will be derived from this project.

  • The first study will establish external validation of the DS tool using Norwegian registry data and assess inter-rater reliability. To the best of our knowledge, this is the first systematic assessment of DS interpretations among surgeons.
  • The second study will provide new insights into how DS may influence patients' expectations.
  • The third study will evaluate whether the use of DS improves surgical outcomes by providing better patient information. Ongoing studies on DS tools compare results from the DS tool with either historical data or results from other regions that do not use the DS tool. This RCT will compare patients from the same region and time period, ensuring equal surgical techniques and mindsets.
  • The fourth study will assess whether the use of DS can reduce surgery cancellations and thereby contribute new data to health services research on efficiency, cost-effectiveness, and resource allocation in surgical care.

The primary outcome measure is the difference in mean ODI between the groups. We have deliberately chosen a target value of 5 points. Many studies are powered to detect differences of around 10 points, which is a relatively large difference; detecting or refuting it requires far fewer participants. In the present context, the study group considered a target value of 5 points a more appropriate aim for determining whether the intervention with an additional DS consultation would justify the use of resources and its implementation in clinical practice.

The primary analysis will be based on the intention-to-treat principle, whereby all randomised patients will be analysed according to the study arm to which they were originally assigned, regardless of protocol deviations. Patients who discontinue participation or are lost to follow-up will remain included in the intention-to-treat population. Additionally, a per-protocol analysis, including only patients who strictly adhere to the study protocol, will be performed and reported. Subgroup analysis will be conducted according to diagnosis category: disc herniation, spinal stenosis, and degenerative disc disease.

A statistician blinded to treatment allocation will analyse the primary and secondary outcome measures using masked group labels. Data will be analysed using standard methods, with descriptive statistics including means and 95% confidence intervals (CIs) for continuous variables and numbers with proportions for categorical variables. The main analyses comparing the two study groups will be based on Student's t-tests for independent groups (continuous outcomes) and chi-square tests (categorical outcomes). Where appropriate, mixed-effects models will be used to account for missing data. The study database will be locked before the final statistical analyses are initiated, after which no further data entry or modification will be permitted. A separate Statistical Analysis Plan (SAP) will provide detailed specifications for the planned analyses, including handling of missing data. The SAP will be finalised, dated, and signed before database lock and made publicly available through ClinicalTrials.gov. A study group meeting will be organised when 220 patients have completed the 3-month follow-up to review recruitment and response rates. Strategies to address non-response will be considered as needed.

The validation study will be an observational cohort study based on prospectively collected data from the Norwegian Spine Registry, including 1500 patients, with 500 in each of the diagnosis subgroups (disc herniation, spinal stenosis, or degenerative disc disease).

02

Conditions studied

  • Spinal Stenosis Lumbar
  • Disc Herniation, Lumbar
  • Degenrative Disc Disease

Keywords

  • Dialogue Support
  • Shared decision-making
  • Predictive tool
  • Spine surgery
  • Randomized Controlled Trial
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients scheduled to undergo lumbar spinal surgery for disc herniation, spinal stenosis, or degenerative disc disease.

Exclusion criteria

Exclusion Criteria:

  • Patients who do not understand spoken or written Norwegian will be excluded, as language barriers may interfere with the intervention consultation, comprehension of the information provided, and completion of study questionnaires. Other exclusion criteria are patients with spondylolysis or lytic spondylolisthesis, as well as patients already participating in other clinical studies.
04

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
440 participants (estimated)

Study arms

  • No intervention
    Standart Care

    No additional consultation prior to the planned surgery

  • Active comparator
    Dialogue Support Consultation

    one additional consultation using the Dialogue Support tool prior to the planned surgery

    Behavioral: Dialogue Support Consultation

Interventions

  • BehavioralDialogue Support Consultation

    This consultation will be scheduled approximately 2-6 weeks prior to surgery. The consultation will occur in the outpatient clinic and is expected to last approximately 30 to 40 minutes. It will be conducted in person to facilitate communication. During the consultation, the DS results are presented and explained to the patient.

05

What researchers measure

Primary outcomes

  1. Oswestry Disability Index (ODI)

    Disability measured using the Oswestry Disability Index (ODI), ranging from 0 to 100, with higher scores indicating greater disability. Mean ODI scores will be compared between the intervention and control groups.

    Time frame: 12 months follow-up

Secondary outcomes

  1. Successful Outcome According to Global Perceived Effect (GPE)

    Proportion of participants achieving a successful outcome, defined as GPE grade 1 (completely recovered) or grade 2 (much better). The proportion of successful outcomes will be compared between groups.

    Time frame: 3 months and 12 months follow-up

  2. ≥30% Improvement in Oswestry Disability Index (ODI)

    Proportion of participants achieving at least a 30% improvement in ODI score from baseline.

    Time frame: 3 months and 12 months follow-up

  3. Oswestry Disability Index (ODI)

    Mean ODI scores will be compared between groups.

    Time frame: 3 months follow-up

  4. Patient Expectations for Postoperative Disability

    Patient expectations assessed preoperatively as the expected postoperative ODI score. Mean expected ODI scores will be compared between groups.

    Time frame: After randomization and before surgery

  5. Cancellation of Planned Spine Surgery

    Proportion of participants whose planned spine surgery is cancelled before the scheduled procedure. The proportion will be compared between groups.

    Time frame: From randomization until the scheduled surgery

  6. EuroQol 5-Dimension 5-Level (EQ-5D-5L)

    Health-related quality of life measured using the EQ-5D-5L questionnaire. Responses will be converted to an index score (from -0.59 to 1), with higher values indicating better health-related quality of life.

    Time frame: 3 months and 12 months follow-up

06

Study locations

2 sites
  • Akershus University Hospital
    Oslo, Nordbyhagen 1478, Norway
  • Innlandet Hospital Trust.
    Gjøvik, 2819, Norway
07

References and documents

Publications

  • Hopewell S, Chan AW, Collins GS, Hrobjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegfried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials. Lancet. 2025 Apr 14:S0140-6736(25)00672-5. doi: 10.1016/S0140-6736(25)00672-5. Online ahead of print. PubMed 40245901 ↗
  • Taylor RS, Taylor RJ. The economic impact of failed back surgery syndrome. Br J Pain. 2012 Nov;6(4):174-81. doi: 10.1177/2049463712470887. PubMed 26516490 ↗
  • Ferreira GE, Zadro J, Liu C, Harris IA, Maher CG. Second opinions for spinal surgery: a scoping review. BMC Health Serv Res. 2022 Mar 18;22(1):358. doi: 10.1186/s12913-022-07771-3. PubMed 35300677 ↗
  • Fritzell P, Mesterton J, Hagg O. Prediction of outcome after spinal surgery-using The Dialogue Support based on the Swedish national quality register. Eur Spine J. 2022 Apr;31(4):889-900. doi: 10.1007/s00586-021-07065-y. Epub 2021 Nov 27. PubMed 34837113 ↗
  • Wellington IJ, Karsmarski OP, Murphy KV, Shuman ME, Ng MK, Antonacci CL. The use of machine learning for predicting candidates for outpatient spine surgery: a review. J Spine Surg. 2023 Sep 22;9(3):323-330. doi: 10.21037/jss-22-121. Epub 2023 Jul 6. PubMed 37841781 ↗
  • Giordano C, Brennan M, Mohamed B, Rashidi P, Modave F, Tighe P. Accessing Artificial Intelligence for Clinical Decision-Making. Front Digit Health. 2021 Jun 25;3:645232. doi: 10.3389/fdgth.2021.645232. eCollection 2021. PubMed 34713115 ↗
  • Pedersen CF, Andersen MO, Carreon LY, Eiskjaer S. Validating the predictive precision of the dialogue support tool on Danish patient cohorts. N Am Spine Soc J. 2022 Dec 2;13:100188. doi: 10.1016/j.xnsj.2022.100188. eCollection 2023 Mar. PubMed 36579158 ↗
  • Grundnes IB, Alhaug OK, Reis JABPRD, Jakobsen RB. Expectations in patients undergoing spine surgery are high and unmet. Spine J. 2024 Dec;24(12):2224-2231. doi: 10.1016/j.spinee.2024.09.004. Epub 2024 Sep 19. PubMed 39303830 ↗
  • Alhaug OK, Dolatowski FC, Solberg TK, Lonne G. Predictors for failure after surgery for lumbar spinal stenosis: a prospective observational study. Spine J. 2023 Feb;23(2):261-270. doi: 10.1016/j.spinee.2022.10.010. Epub 2022 Nov 5. PubMed 36343913 ↗
  • Solberg TK, Ingebrigtsen T, Thyrhaug AM, Olsen LR. Annual Report 2024 National Quality Register for Spinal Surgery (NORSpine). Septentrio Reports. 2025(2).

Individual participant data

Plan to share: No — The study results will be disseminated through scientific publications following completion of data collection and analysis

08

Registry details

Key details

Study ID
NCT07788872
Lead sponsor
University Hospital, Akershus
Collaborators
Sykehuset Innlandet HF
Responsible party
Per-Henrik Randsborg (Professor, University Hospital, Akershus) — Principal investigator
First posted
Aug 27, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Sep 1, 2029 (estimated)
Completion
Sep 1, 2031 (estimated)
Last update
Aug 27, 2026

Study contacts

João Reis, MD
Contact
jorore@ahus.no
+47 67 96 00 00
Ole Kristian Alhaug, MD, PhD
Contact
ole.kristian.alhaug@ahus.no
+47 67 96 00 00
Per-Henrik Randsborg, MD, PhD
principal investigator · University Hospital, Akershus

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion